Innovation with community – JDRF
Brevitas is delighted to support JDRF’s work with a $1,000 donation which is going towards their One-Walk fundraising event for their Charity. We are happy to be able to contribute to their cause and are excited to see their continued success in finding a cure for T1D.
Since its inception in 1970, JDRF’s relentless pursuit of a cure for T1D is driven by its commitment to transforming the lives of individuals affected by the condition. Through the Improving Lives Program, the organization continues to spearhead cutting-edge research, revolutionize treatment options, and address the diverse challenges faced by those living with T1D. With a focus on innovation, JDRF remains at the forefront of advancements that aim to improve outcomes and quality of life for T1D patients worldwide. In the past decade JDRF has invested more than $245 million in Improving Lives.
JDRF focuses on advancing the development of new drugs and devices that enable T1D patients to lead longer and healthier lives. This includes.
- Novel insulins, e.g., glucose-responsive, ultra-rapid, and liver-targeted.
- Adjunctive therapies in addition to insulin that make it easier to live with T1D, e.g., SGLT inhibitors, insulin and pramlintide co-formulations, and others; and
- Smaller, easier to wear insulin pumps and continuous glucose monitors with improved algorithms that shoulder more of the burden of T1D.